CLINICAL TRIALS PROFILE FOR DROSPIRENONE
✉ Email this page to a colleague
All Clinical Trials for drospirenone
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00102141 ↗ | Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women | Completed | Bayer | Phase 3 | 2004-04-01 | The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension. |
NCT00185419 ↗ | A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception | Completed | Bayer | Phase 3 | 2003-11-01 | The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in healthy Chinese women |
NCT00185484 ↗ | Efficacy and Safety Oral Contraceptive Study | Completed | Bayer | Phase 3 | 2004-03-01 | The purpose of this study is to determine whether the study drug is effective in prevention of pregnancy in healthy women in reproductive age |
NCT00266032 ↗ | Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles | Completed | Bayer | Phase 3 | 2005-12-01 | The purpose of the study is to determine safety and efficacy of long-cycle regimens of an oral contraceptive. |
NCT00302848 ↗ | European Active Surveillance Study (EURAS) | Completed | Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma | 2000-11-01 | EURAS is a multi-national, controlled, prospective, post-marketing, non-intervention cohort study of new users of drospirenone/ethinylestradiol (DRSP/EE), levonorgestrel/ethinylestradiol (LNG/EE) and other oral contraceptives (OCs) under routine conditions of medical practice in seven European countries. Baseline survey and semiannual, active follow-up are based on postal questionnaires, with validation of reported events by the women's treating physicians. A multifaceted 4-level follow-up procedure will be established to ensure low loss to follow-up rates. The objective of the study is the investigation of the incidence of rare serious adverse events associated with the use of new and established OCs, and specifically the incidence of thromboembolic events. | |
NCT00302848 ↗ | European Active Surveillance Study (EURAS) | Completed | Center for Epidemiology and Health Research, Germany | 2000-11-01 | EURAS is a multi-national, controlled, prospective, post-marketing, non-intervention cohort study of new users of drospirenone/ethinylestradiol (DRSP/EE), levonorgestrel/ethinylestradiol (LNG/EE) and other oral contraceptives (OCs) under routine conditions of medical practice in seven European countries. Baseline survey and semiannual, active follow-up are based on postal questionnaires, with validation of reported events by the women's treating physicians. A multifaceted 4-level follow-up procedure will be established to ensure low loss to follow-up rates. The objective of the study is the investigation of the incidence of rare serious adverse events associated with the use of new and established OCs, and specifically the incidence of thromboembolic events. | |
NCT00356447 ↗ | Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. | Completed | Bayer | Phase 3 | 2006-05-01 | The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro-genital complaints. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for drospirenone
Condition Name
Clinical Trial Locations for drospirenone
Trials by Country
Clinical Trial Progress for drospirenone
Clinical Trial Phase
Clinical Trial Sponsors for drospirenone
Sponsor Name